ArticleMedical oncology (Northwood, London, England)2010
Knockdown of HBx by RNAi inhibits proliferation and enhances chemotherapy-induced apoptosis in hepatocellular carcinoma cells.
Article in Medical oncology (Northwood, London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 15 citations in OpenAlex.
- The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma.Clinical and experimental medicine · 2025Review
- Nuclear IKKα mediates microRNA-7/-103/107/21 inductions to downregulate maspin expression in response to HBx overexpression.Oncotarget · 2016Article
- The hepatitis B virus x protein inhibits thymine DNA glycosylase initiated base excision repair.PloS one · 2012Article
- Hepatitis B virus X gene and hepatocarcinogenesis.Journal of gastroenterology · 2011Review
- Hepatitis B virus X protein impedes the DNA repair via its association with transcription factor, TFIIH.BMC microbiology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study was designed to research on RNA interference hepatitis B virus x gene approach to hepatocellular carcinoma (HCC) therapy. Previously, we constructed and identified shRNA eukaryotic expression vectors (pshRNA-X220) specific to HBx gene, pshRNA-MOCK (control); and established HCC cell lines with stable expression shRNA eukaryotic vector targeting HBx gene-21543 cell lines (MHCC97-H of expressing shRNA against HBx), HK3 cell lines (MHCC97-H by transfected with pshRNA-MOCK). We examined the expression of HBx gene after RNA interference by semi-quantitative RT-PCR and assessed the effect of HBx knocked down on cell growth by proliferation assay using kit-8 (CCK8). As well as, we analyzed cell cycle distribution by flowcytometry and examined cell apoptosis using TUNEL assay. The HBx mRNA expression level is reduced, and cells growth was significantly stopped in 21543 cell lines. Cells with HBx knockdown were more sensitive to 5-fluorouracil/cisplatin. RNA interfering HBx induced an obvious time and dose-dependent inhibitory in comparison with the control cells. Meanwhile, RNA interferenced targeting HBx, in combination with chemotherapy can effectively induce apoptosis in hepatocellular carcinoma cells and restricts cell proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.